Sujith Ramachandran, PhD, associate director of Trinity Life Sciences, grouped access barriers into 3 buckets: upfront ...

A clinical-note analysis of more than 1000 patients found rising off-label BPC-157 use for pain and healing, with outcomes ...

The number of approvals is really only 1 piece of the pie,” said Nicole A. Caffiero, PharmD, MBA, BCACP, senior clinical ...

Frailty, but not HIV serostatus, is tied to more severe lower urinary tract symptoms in adults with and at risk for HIV, a ...

At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push ...

T2D-2, retatrutide lowered A1C 2.2 points vs 1.8 with semaglutide 2 mg and more than doubled weight loss at 80 weeks.

Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.

At AMCP Nexus 2026, Susan M. Wescott, RPh, MBA, discussed how health plans evaluate rare disease therapies amid limited data and high costs.

Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access ...

A poster at the ASCO Quality Care Symposium describes how a value-based care partnership used prior authorization data and ...

James D. Chambers, PhD, MPharm, MSc, discusses US biosimilar adoption and opportunities to expand patient access and lower ...

Sputum is considered a noninvasive marker of airway inflammation, and its color is an indicator of bronchiectasis disease ...